Verlytix Launches Analytical Lab to Standardize Peptide Testing

Verlytix, formerly known as MPP Group, is leveraging its existing pharmaceutical and biological testing infrastructure to address a significant gap in the peptide industry. The company operates under cGMP standards and received an FDA Establishment Inspection Report in 2024, providing a regulatory foundation for its expansion. Its core service platform covers the entire drug development lifecycle, from preclinical formulation and stability storage to commercial quality control.

Tommy Thompson, Chairman of Vector Science & Therapeutics, noted that this launch formalizes a long-standing focus on analytical precision. By integrating its testing capabilities with Vector’s broader peptide portfolio, Verlytix intends to become a primary resource for manufacturers struggling with the inherent variability of peptide products. CEO Bill Jackson confirmed that the laboratory will now apply its microbial and analytical expertise directly to peptide potency and purity, aiming to provide the transparency currently missing in the rapidly scaling sector.